Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;46(7):1305-1316.
doi: 10.1007/s40618-023-02036-0. Epub 2023 Feb 18.

Dysthyroid optic neuropathy: emerging treatment strategies

M Pelewicz-Sowa  1 , P Miśkiewicz  2
Affiliations
Review

Dysthyroid optic neuropathy: emerging treatment strategies

M Pelewicz-Sowa et al. J Endocrinol Invest. 2023 Jul.

Abstract

Purpose: Dysthyroid optic neuropathy (DON) is a rare sight-threatening complication of Graves' disease. First-line treatment for DON consists of high-dose intravenous methylprednisolone (ivMP), followed by immediate orbital decompression (OD) if the response is poor or absent as recommended by the 2021 European Group on Graves' orbitopathy guidelines. The safety and efficacy of the proposed therapy have been proven. However, consensus regarding possible therapeutic options for patients with contraindications to ivMP/OD or resistant form of disease is missing. This paper aims to provide and summarize all available data regarding possible alternative treatment strategies for DON.

Methods: A comprehensive literature search within an electronic database was performed including data published until December 2022.

Results: Overall, 52 articles describing use of emerging therapeutic strategies for DON were identified. Collected evidence indicates that biologics, including teprotumumab and tocilizumab, may be considered as an important possible treatment option for DON patients. Rituximab should be avoided in DON due to conflicting data and risk of adverse events. Orbital radiotherapy could be beneficial for patients with restricted ocular motility classified as poor surgical candidates.

Conclusion: Only a limited number of studies have been dedicated to the therapy of DON, mostly retrospective with a small sample size. Clear criteria regarding diagnosis and resolution of DON do not exist, which restricts comparison of therapeutic outcomes. Randomized clinical trials and comparison studies with long-term follow-ups are necessary to verify the safety and efficacy of each therapeutic option for DON.

Keywords: Dysthyroid optic neuropathy; Graves’ orbitopathy; Methylprednisolone; Rituximab; Teprotumumab; Tocilizumab.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

References

    1. Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of graves’ orbitopathy. Front Endocrinol. 2020;11:615993. doi: 10.3389/fendo.2020.615993. - DOI - PMC - PubMed
    1. Wiersinga WM. Autoimmunity in graves’ ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab. 2011;96(8):2386–2394. doi: 10.1210/jc.2011-0307. - DOI - PubMed
    1. Neag EJ, Smith TJ. 2021 update on thyroid-associated ophthalmopathy. J Endocrinol Invest. 2022;45(2):235–259. doi: 10.1007/s40618-021-01663-9. - DOI - PMC - PubMed
    1. Kahaly GJ. Management of graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab. 2020;105(12):3704–3720. doi: 10.1210/clinem/dgaa646. - DOI - PMC - PubMed
    1. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–290. doi: 10.1016/S0002-9394(14)70276-4. - DOI - PubMed